One-year Outcome of Intravitreal Dexamethasone Implant for Macular Edema Secondary to Central Retinal Vein Occlusion.

Published on Dec 15, 2016in Journal of The Korean Ophthalmological Society
· DOI :10.3341/JKOS.2016.57.12.1918
Tae Hoon Kim3
Estimated H-index: 3
(Inje University),
Tae Hoon Kim2
Estimated H-index: 2
(Inje University)
+ 5 AuthorsHyun Woong Kim14
Estimated H-index: 14
(Inje University)
Sources
Abstract
📖 Papers frequently viewed together
References24
Newest
Purpose To review published data pertaining to the clinical experience with a dexamethasone intravitreal implant (Ozurdex®) with a view to establishing a clinically based therapeutic regime.
24 CitationsSource
#1Ji Young Lee (Konkuk University)H-Index: 13
#2Hyung Chan Kim (Konkuk University)H-Index: 20
3 CitationsSource
#1Pravin U. DugelH-Index: 51
#2Antonio CaponeH-Index: 36
Last. David A. Hollander (Allergan)H-Index: 23
view all 10 authors...
Background: Dexamethasone intravitreal implant (DEX implant) is a biodegradable, sustained-release implant that releases dexamethasone for up to 6 months. We evaluated the efficacy and safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients. Methods: A multicenter, retrospective, open-label chart review study investigated the efficacy and safety of DEX implant treatment in 289 patients with macular edema secondary to branch or...
11 CitationsSource
#1Jeffrey S. HeierH-Index: 57
#2W. Lloyd ClarkH-Index: 16
Last. Julia A. Haller (Wills Eye Institute)H-Index: 60
view all 12 authors...
Purpose To evaluate the efficacy and safety of intravitreal aflibercept injection (IAI) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). Design Randomized, double-masked, phase 3 trial. Participants A total of 188 patients with macular edema secondary to CRVO. Methods Patients received IAI 2 mg (IAI 2Q4) (n = 114) or sham injections (n = 74) every 4 weeks up to week 24. During weeks 24 to 52, patients from both arms were evaluated monthly and received IAI as...
177 CitationsSource
#1Antonio Capone (RU: Rutgers University)H-Index: 1
#2Michael A. Singer (Oakland University)H-Index: 1
Last. David A. HollanderH-Index: 23
view all 9 authors...
Purpose:To evaluate the efficacy, safety, and reinjection interval of dexamethasone intravitreal implant (DEX implant) in branch retinal vein occlusion and central retinal vein occlusion patients receiving ≥2 DEX implant treatments.Methods:Multicenter (26-site), retrospective chart review study. Dat
76 CitationsSource
#1Jean-François Korobelnik (Université Bordeaux Segalen)H-Index: 39
#2Frank G. Holz (University of Bonn)H-Index: 88
Last. Rupert Sandbrink (HHU: University of Düsseldorf)H-Index: 33
view all 14 authors...
Purpose To evaluate the efficacy and safety of intravitreal aflibercept injections for treatment of macular edema secondary to central retinal vein occlusion (CRVO). Design A randomized, multicenter, double-masked phase 3 study. Participants A total of 177 treatment-naive patients with macular edema secondary to CRVO were randomized in a 3:2 ratio. Methods Patients received either 2-mg intravitreal aflibercept or sham injections every 4 weeks for 20 weeks. From week 24 to 48, the aflibercept gro...
177 CitationsSource
#1Lavnish Joshi (UCL Institute of Ophthalmology)H-Index: 14
#2Satish Yaganti (Royal Surrey County Hospital)H-Index: 3
Last. Simon R J Taylor (Imperial College London)H-Index: 26
view all 9 authors...
Objective To report the 12-month outcomes of the dexamethasone intravitreal implant in retinal vein occlusion (RVO), using an as-needed repeat injection protocol. Design Retrospective consecutive case series of 51 eyes of 49 patients with macular oedema as a result of RVO that received an intravitreal dexamethasone implant and were followed up for at least 12 months. Results 70% of patients responded to dexamethasone implant injection with an improvement in visual acuity (VA) and macular oedema ...
41 CitationsSource
#1Elad Moisseiev (TAU: Tel Aviv University)H-Index: 20
#2Michaella Goldstein (TAU: Tel Aviv University)H-Index: 18
Last. Anat Loewenstein (TAU: Tel Aviv University)H-Index: 28
view all 5 authors...
Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion
43 CitationsSource
#1Han ZhangH-Index: 10
#2Zhe-Li LiuH-Index: 9
Last. Feng GuH-Index: 5
view all 4 authors...
Abstract Purpose: The purpose of this article was to evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with macular edema secondary to central retinal vein occlusion (CRVO). Methods: Forty-five consecutive eyes with macular edema secondary to CRVO were included in a prospective clinical trial. Eyes were treated with 3 initial intravitreal bevacizumab injections of 1.25 mg at monthly intervals. Retreatment was based on central retinal thickness (CRT) measured by optic...
22 CitationsSource
#1Julia A. Haller (Wills Eye Institute)H-Index: 60
#2Francesco BandelloH-Index: 64
Last. Scott M. Whitcup (Allergan)H-Index: 25
view all 11 authors...
Objective To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (DEX implant) over 12 months in eyes with macular edema owing to branch or central retinal vein occlusion (BRVO or CRVO). Design Two identical, multicenter, prospective studies included a randomized, 6-month, double-masked, sham-controlled phase followed by a 6-month open-label extension. Participants We included 1256 patients with vision loss owing to macular edema associated with BRVO or ...
486 CitationsSource
Cited By4
Newest
Source
#1Hyun Ji Kang (Gyeongsang National University)H-Index: 1
#2Yong Wun Cho (Gyeongsang National University)H-Index: 2
Last. Woong Sun Yoo (Gyeongsang National University)H-Index: 5
view all 7 authors...
Source
#1No Hae Park (Inje University)H-Index: 1
#2Hyun Duck Kwak (Inje University)H-Index: 2
Last. Hyun Woong Kim (Inje University)H-Index: 14
view all 9 authors...
Source
#1Han SongH-Index: 1
#2Hee Jun SongH-Index: 1
Last. Do Gyun KimH-Index: 3
view all 4 authors...
1 CitationsSource